Welcome to our dedicated page for Cytokinetics news (Ticker: CYTK), a resource for investors and traders seeking the latest updates and insights on Cytokinetics stock.
Cytokinetics, Incorporated develops and commercializes muscle-directed cardiovascular medicines, led by MYQORZO® (aficamten), a cardiac myosin inhibitor approved in the U.S., Europe and China for adults with symptomatic obstructive hypertrophic cardiomyopathy. Company news regularly covers MYQORZO clinical data, launch activity, regulatory approvals and analyses from HCM studies including SEQUOIA-HCM, MAPLE-HCM, FOREST-HCM and ACACIA-HCM.
Recurring updates also address Cytokinetics’ pipeline in cardiac muscle dysfunction, including omecamtiv mecarbil for heart failure with severely reduced ejection fraction and ulacamten for heart failure with preserved ejection fraction. Financial releases and corporate announcements include product revenue, operating updates, shareholder voting matters, common stock offerings and other capital-structure developments.
Cytokinetics (Nasdaq: CYTK) granted inducement equity awards on March 13, 2026 to five new employees hired in February–March 2026: 8,628 stock options and 5,719 RSUs. Options carry a $60.06 exercise price and 10-year term; RSUs vest over three years per schedule. Awards follow Nasdaq Listing Rule 5635(c)(4) and are subject to the company's 2004 Equity Incentive Plan and award agreements.
Cytokinetics (Nasdaq: CYTK) announced four ACC 2026 presentations on MYQORZO (aficamten) for symptomatic obstructive hypertrophic cardiomyopathy (oHCM), including pooled and subgroup analyses, treatment interruption data, hypertension subgroup results, and ECG‑echocardiography correlations.
Notable facts: regulatory approvals in US, EU, and China; pooled n=371; washout analysis n=182; ECG odds ratios significant (p<0.001).
Cytokinetics (NASDAQ: CYTK) said members of its management team will participate in four investor events in Miami Beach in March 2026: Leerink Global Healthcare (fireside, Mar 9), Citizens Life Sciences (fireside, Mar 10), Jefferies Biotech on the Beach (one-on-ones, Mar 11), and Barclays Global Healthcare (fireside, Mar 11).
Live webcasts of the fireside chats will be available via the company's Investors & Media website, with replay archives retained for 90 days after each event.
Cytokinetics (Nasdaq: CYTK) reported Q4 and full-year 2025 results, announced multi-region approvals for MYQORZO (aficamten), and began U.S. commercial launch with first prescriptions dispensed. The company ended 2025 with ~$1.22 billion in cash, reported full‑year 2025 revenue of $88.0 million, and provided 2026 GAAP R&D+SG&A guidance of $830–870 million.
Key upcoming milestones include ACACIA‑HCM topline in Q2 2026, a Germany launch in Q2 2026, and a potential MAPLE‑HCM sNDA decision in Q4 2026.
Cytokinetics (Nasdaq: CYTK) announced European Commission approval of MYQORZO (aficamten) 5 mg, 10 mg, 15 mg and 20 mg tablets to treat symptomatic obstructive hypertrophic cardiomyopathy (NYHA class II-III) in adults. First European launch is planned in Germany in Q2 2026; label allows starting doses of 5 mg or 10 mg.
The EC decision follows a positive CHMP opinion and joins prior approvals by the FDA and China NMPA.
Cytokinetics (Nasdaq: CYTK) will report fourth quarter results on February 24, 2026 at 4:00 PM ET, followed by a management conference call at 4:30 PM ET.
According to the company, the call will be webcast and accessible via the Investors & Media section of Cytokinetics' website, with an archived replay available for six months.
Cytokinetics (Nasdaq: CYTK) announced recipients of its eighth annual Communications Grant Program on February 9, 2026, awarding two grants to patient advocacy organizations serving the hypertrophic cardiomyopathy (HCM) community.
The grants fund digital communications, bilingual video resources, a pediatric clinic toolkit, and a six-month Canadian awareness campaign to expand HCM education and community engagement.
Cytokinetics (NASDAQ: CYTK) launched "On Track with HCM" on January 27, 2026, an awareness and support program focused on the whole-person impact of hypertrophic cardiomyopathy (HCM). The campaign features Olympic gold medalist Sydney McLaughlin-Levrone, her father Willie McLaughlin who lived with non-obstructive HCM before a heart transplant, and cardiologist Melissa Burroughs, MD. The program includes a dedicated website, OnTrackWithHCM.com, and eight original videos offering personal stories, clinical context, and practical guidance on fitness, nutrition, rest, social and family challenges for people living with HCM. The release reiterates that HCM affects up to 1 in 350 people and increases risk for atrial fibrillation, heart failure, and sudden cardiac arrest.
Cytokinetics (NASDAQ: CYTK) announced that MYQORZO (aficamten) is now available by prescription in the U.S. in 5 mg, 10 mg, 15 mg and 20 mg tablets following FDA approval on Dec 19, 2025.
MYQORZO is a once-daily oral cardiac myosin inhibitor indicated for adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms. The prescribing information includes a Boxed WARNING for heart failure risk; initiation is not recommended in patients with LVEF <55% and echocardiogram monitoring is required. MYQORZO is available only through a REMS program. Cytokinetics launched patient support services and specialty pharmacy distribution concurrent with availability.
Cytokinetics (Nasdaq: CYTK) announced inducement equity awards granted on January 15, 2026 to eight new employees hired in December 2025 and January 2026. The company granted options to purchase 29,416 shares and 19,825 restricted stock units (RSUs) that will settle in common stock upon vesting.
The RSUs vest over 3 years (40% at year 1, 40% at year 2, 20% at year 3). The options vest over 4 years (25% at year 1, then monthly over 36 months), carry a $63.44 exercise price (equal to the closing price on January 15, 2026) and have a 10-year term. Awards are subject to the company's equity plan and Nasdaq Listing Rule 5635(c)(4).